StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Jefferies Reiterates Buy Rating on Amgen (AMGN) as Lumakras Phase III CB200 Hits
August 31, 2022 8:29 AM
Jefferies analyst Michael Yee reiterated a Buy rating and $295.00 price target on Amgen (NASDAQ: AMGN) after Lumakras Phase III ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
After-Hours Movers: Chargepoint Gains Following Results, Chewy Falls
August 30, 2022 5:24 PM
Amgen (AMGN) Reports Phase 3 CodeBreaK 200 trial of Lumakras Met Primary Endpoint
August 30, 2022 4:04 PM
AMGEN ANNOUNCES TOPLINE DATA FROM LUMAKRAS® (SOTORASIB) PHASE 3 TRIAL IN NON-SMALL CELL LUNG CANCER
August 30, 2022 4:03 PM
AMGEN TO PRESENT NEW, POSITIVE CLINICAL AND REAL-WORLD DATA ACROSS INFLAMMATION PORTFOLIO AT EADV 2022
August 30, 2022 9:00 AM
NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® (EVOLOCUMAB) WAS WELL-TOLERATED FOR MORE THAN 8 YEARS
August 29, 2022 3:10 AM
_58cbc46cd3c33.jpg)
